Paris Panayiotopoulos - Net Worth and Insider Trading
Paris Panayiotopoulos Net Worth
The estimated net worth of Paris Panayiotopoulos is at least $2 Million dollars as of 2024-12-27. Paris Panayiotopoulos is the President and CEO of ARIAD Pharmaceuticals Inc and owns about 61,099 shares of ARIAD Pharmaceuticals Inc (ARIA) stock worth over $1 Million. Paris Panayiotopoulos is the Director of The Medicines Co and owns about 6,452 shares of The Medicines Co (MDCO) stock worth over $547,775. Paris Panayiotopoulos is also the Director of Corbus Pharmaceuticals Holdings Inc and owns about 476 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) stock worth over $6,255. Details can be seen in Paris Panayiotopoulos's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paris Panayiotopoulos has not made any transactions after 2017-11-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Paris Panayiotopoulos
Paris Panayiotopoulos Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paris Panayiotopoulos owns 3 companies in total, including The Medicines Co (MDCO) , Corbus Pharmaceuticals Holdings Inc (CRBP) , and ARIAD Pharmaceuticals Inc (ARIA) .
Click here to see the complete history of Paris Panayiotopoulos’s form 4 insider trades.
Insider Ownership Summary of Paris Panayiotopoulos
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MDCO | The Medicines Co | 2020-01-06 | director |
| CRBP | Corbus Pharmaceuticals Holdings Inc | 2017-11-16 | director |
| ARIA | ARIAD Pharmaceuticals Inc | 2017-02-16 | director & President and CEO |
Paris Panayiotopoulos Latest Holdings Summary
Paris Panayiotopoulos currently owns a total of 3 stocks. Among these stocks, Paris Panayiotopoulos owns 61,099 shares of ARIAD Pharmaceuticals Inc (ARIA) as of May 12, 2016, with a value of $1 Million and a weighting of 72.57%. Paris Panayiotopoulos owns 6,452 shares of The Medicines Co (MDCO) as of November 30, 2017, with a value of $547,775 and a weighting of 27.12%. Paris Panayiotopoulos also owns 476 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) as of November 16, 2017, with a value of $6,255 and a weighting of 0.31%.
Latest Holdings of Paris Panayiotopoulos
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ARIA | ARIAD Pharmaceuticals Inc | 2016-05-12 | 61,099 | 23.99 | 1,465,765 |
| MDCO | The Medicines Co | 2017-11-30 | 6,452 | 84.90 | 547,775 |
| CRBP | Corbus Pharmaceuticals Holdings Inc | 2017-11-16 | 476 | 13.14 | 6,255 |
Holding Weightings of Paris Panayiotopoulos
Paris Panayiotopoulos Form 4 Trading Tracker
According to the SEC Form 4 filings, Paris Panayiotopoulos has made a total of 0 transactions in ARIAD Pharmaceuticals Inc (ARIA) over the past 5 years. The most-recent trade in ARIAD Pharmaceuticals Inc is the acquisition of 26,990 shares on May 12, 2016, which cost Paris Panayiotopoulos around $199,996.
According to the SEC Form 4 filings, Paris Panayiotopoulos has made a total of 0 transactions in The Medicines Co (MDCO) over the past 5 years. The most-recent trade in The Medicines Co is the acquisition of 3,215 shares on November 30, 2017, which cost Paris Panayiotopoulos around $99,569.
According to the SEC Form 4 filings, Paris Panayiotopoulos has made a total of 0 transactions in Corbus Pharmaceuticals Holdings Inc (CRBP) over the past 5 years. The most-recent trade in Corbus Pharmaceuticals Holdings Inc is the acquisition of 476 shares on November 16, 2017, which cost Paris Panayiotopoulos around $100,424.
Insider Trading History of Paris Panayiotopoulos
- 1
Paris Panayiotopoulos Trading Performance
GuruFocus tracks the stock performance after each of Paris Panayiotopoulos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paris Panayiotopoulos is 28.57%. GuruFocus also compares Paris Panayiotopoulos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paris Panayiotopoulos within 3 months outperforms 4 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paris Panayiotopoulos's insider trading performs compared to the benchmark.
Performance of Paris Panayiotopoulos
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 5.9 | | | | | |
| Relative Return to S&P 500(%) | 3.9 | | | | | |
Paris Panayiotopoulos Ownership Network
Paris Panayiotopoulos Owned Company Details
What does The Medicines Co do?
Who are the key executives at The Medicines Co?
Paris Panayiotopoulos is the director of The Medicines Co. Other key executives at The Medicines Co include Chief Development Officer Peter Wijngaard , EVP & Chief Corp. Dev. Officer Christopher T Cox , and director & Executive Chairman Fredric N Eshelman .
The Medicines Co (MDCO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of The Medicines Co (MDCO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of The Medicines Co (MDCO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
The Medicines Co (MDCO)'s detailed insider trading history can be found in Insider Trading Tracker table.
The Medicines Co Insider Transactions
Paris Panayiotopoulos Mailing Address
Above is the net worth, insider trading, and ownership report for Paris Panayiotopoulos. You might contact Paris Panayiotopoulos via mailing address: Ariad Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
